Notification

🚨 Trading Holiday 🚨

The NSE and BSE will remain closed for trading and settlement on Monday, April 14, 2025, on account of Dr. B. R. Ambedkar Jayanti.

Open a Free Demat Account

Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.

Trade Now, Pay Later with up to 4x

Never miss a good trading opportunity due to low funds with our MTF feature.

Track Market Movers Instantly

Stay updated with real-time data. Get insights at your fingertips.

NSE BSE

Trade Nowopens in a new tab

Birla Precision Technologies L Share Price

₹ 39.57 0.18 (0.45%)

Apr 15 2025 03:28 PM Capital Goods-Non Electrical Equipment NSE: BIRLAPREC

Birla Precision Technologies L Share Price Update

As of the latest trading session, Birla Precision Technologies L share price is currently at 39.57, which is up by 0.18 from its previous closing. Today, the stock has fluctuated between 39.01 and 40.45. Over the past year, Birla Precision Technologies L has achieved a return of -37.72 %. In the last month alone, the return has been -0.40 %. Read More...

Birla Precision Technologies L Performance

Day Range

Low39.01 High40.45

39.57

52 Week Range

Low 32.10 High 93.50

39.57

Birla Precision Technologies L Share Price

522105

BIRLAPREC

Compare to down-arrow

View

Display

Studies

No Data Available

Open Price

40.45 Prev. Close

39.39 Volume (Shares)

16317.00

Total traded value

6.46 Upper Circuit

41.54 Lower Circuit

37.60

Note: The current prices & values are delayed, Loginopens in a new tab to your account for live updates.

Birla Precision Technologies L Fundamentals

(Standalone)

Market Cap (Cr)	261.11
PE Ratio (TTM)	303.00
Book Value / Share	22.71
Beta	1.00

ROE	7.46%
EPS (TTM)	0.19
Dividend Yield	0.25%
Net Profit Qtr (Cr)	-0.26

Birla Precision Technologies L Financials

Key Results
Key Ratios
Balance sheet
Cash Flow
Competition

Revenue

Net income

Particulars	DEC 2024 (Values in Cr)
Revenue	53.33
Operating Expense	53.08
Net Profit	-0.26
Net Profit Margin (%)	-0.48
Earnings Per Share (EPS)	-0.04
EBITDA	3.55
Effective Tax Rate (%)	150.94

Particulars	SEP 2024 (Values in Cr)
Revenue	54.95
Operating Expense	52.73
Net Profit	1.99
Net Profit Margin (%)	3.62
Earnings Per Share (EPS)	0.30
EBITDA	5.51
Effective Tax Rate (%)	16.03

Particulars	JUN 2024 (Values in Cr)
Revenue	46.40
Operating Expense	45.50
Net Profit	0.33
Net Profit Margin (%)	0.71
Earnings Per Share (EPS)	0.05
EBITDA	4.18
Effective Tax Rate (%)	61.90

Particulars	MAR 2024 (Values in Cr)
Revenue	60.99
Operating Expense	59.87
Net Profit	-1.19
Net Profit Margin (%)	-1.95
Earnings Per Share (EPS)	-0.18
EBITDA	4.70
Effective Tax Rate (%)	160.10

Particulars	DEC 2023 (Values in Cr)
Revenue	67.29
Operating Expense	58.43
Net Profit	7.06
Net Profit Margin (%)	10.49
Earnings Per Share (EPS)	1.08
EBITDA	11.60
Effective Tax Rate (%)	23.70

Particulars	MAR 2024 (Values in Cr)
Revenue	225.77
Operating Expense	209.78
Net Profit	10.66
Net Profit Margin (%)	4.72
Earnings Per Share (EPS)	1.62
EBITDA	27.98
Effective Tax Rate (%)	40.77

Particulars	MAR 2023 (Values in Cr)
Revenue	253.37
Operating Expense	243.06
Net Profit	15.28
Net Profit Margin (%)	6.03
Earnings Per Share (EPS)	2.34
EBITDA	28.58
Effective Tax Rate (%)	26.00

Particulars	MAR 2022 (Values in Cr)
Revenue	246.27
Operating Expense	237.01
Net Profit	11.18
Net Profit Margin (%)	4.53
Earnings Per Share (EPS)	1.71
EBITDA	20.67
Effective Tax Rate (%)	1.14

Particulars	MAR 2021 (Values in Cr)
Revenue	171.48
Operating Expense	171.87
Net Profit	1.42
Net Profit Margin (%)	0.82
Earnings Per Share (EPS)	0.22
EBITDA	10.92
Effective Tax Rate (%)	2.08

Particulars	MAR 2020 (Values in Cr)
Revenue	173.50
Operating Expense	177.01
Net Profit	-13.31
Net Profit Margin (%)	-7.67
Earnings Per Share (EPS)	-2.34
EBITDA	-2.72
Effective Tax Rate (%)	0.00

Particulars	MAR 2024 (Values in Cr)
Book Value / Share	22.00
ROE %	6.68
ROCE %	11.16
Total Debt to Total Equity	0.27
EBITDA Margin	11.87

Particulars	MAR 2023 (Values in Cr)
Book Value / Share	20.14
ROE %	8.66
ROCE %	11.77
Total Debt to Total Equity	0.23
EBITDA Margin	9.10

Particulars	MAR 2022 (Values in Cr)
Book Value / Share	18.12
ROE %	9.94
ROCE %	11.73
Total Debt to Total Equity	0.23
EBITDA Margin	8.39

Particulars	MAR 2021 (Values in Cr)
Book Value / Share	16.33
ROE %	1.37
ROCE %	4.82
Total Debt to Total Equity	0.26
EBITDA Margin	6.37

Particulars	MAR 2020 (Values in Cr)
Book Value / Share	17.64
ROE %	0.00
ROCE %	4.25
Total Debt to Total Equity	0.28
EBITDA Margin	6.10

Particulars	MAR 2024 (Values in Cr)
Book Value / Share	22.37
ROE %	7.46
ROCE %	11.71
Total Debt to Total Equity	0.27
EBITDA Margin	12.39

Particulars	MAR 2023 (Values in Cr)
Book Value / Share	20.33
ROE %	9.52
ROCE %	12.49
Total Debt to Total Equity	0.23
EBITDA Margin	9.57

Particulars	MAR 2022 (Values in Cr)
Book Value / Share	18.12
ROE %	9.94
ROCE %	11.73
Total Debt to Total Equity	0.23
EBITDA Margin	8.39

Particulars	MAR 2021 (Values in Cr)
Book Value / Share	16.33
ROE %	1.37
ROCE %	4.82
Total Debt to Total Equity	0.26
EBITDA Margin	6.37

Particulars	MAR 2020 (Values in Cr)
Book Value / Share	17.64
ROE %	0.00
ROCE %	4.04
Total Debt to Total Equity	0.27
EBITDA Margin	6.10

Particulars	MAR 2024 (Values in Cr)
Cash & Short Term Investments	24.80
Total Assets	267.60
Total Liabilities	267.60
Total Equity	150.68
Share Outstanding	65987637
Price to Book Ratio	2.65
Return on Assets (%)	3.52
Return on Capital (%)	4.85

Particulars	MAR 2023 (Values in Cr)
Cash & Short Term Investments	26.08
Total Assets	234.69
Total Liabilities	234.69
Total Equity	131.48
Share Outstanding	65271137
Price to Book Ratio	1.64
Return on Assets (%)	5.99
Return on Capital (%)	8.59

Particulars	MAR 2022 (Values in Cr)
Cash & Short Term Investments	20.76
Total Assets	213.93
Total Liabilities	213.93
Total Equity	118.27
Share Outstanding	65271137
Price to Book Ratio	1.43
Return on Assets (%)	5.22
Return on Capital (%)	7.85

Particulars	MAR 2021 (Values in Cr)
Cash & Short Term Investments	23.33
Total Assets	198.77
Total Liabilities	198.77
Total Equity	106.61
Share Outstanding	65271137
Price to Book Ratio	0.61
Return on Assets (%)	0.71
Return on Capital (%)	1.07

Particulars	MAR 2020 (Values in Cr)
Cash & Short Term Investments	8.60
Total Assets	187.79
Total Liabilities	187.79
Total Equity	100.25
Share Outstanding	56839434
Price to Book Ratio	0.25
Return on Assets (%)	-7.08
Return on Capital (%)	-10.55

Particulars	MAR 2024 (Values in Cr)
Cash & Short Term Investments	24.11
Total Assets	269.88
Total Liabilities	269.88
Total Equity	153.12
Share Outstanding	65987637
Price to Book Ratio	2.65
Return on Assets (%)	3.95
Return on Capital (%)	5.42

Particulars	MAR 2023 (Values in Cr)
Cash & Short Term Investments	25.91
Total Assets	235.87
Total Liabilities	235.87
Total Equity	132.69
Share Outstanding	65271137
Price to Book Ratio	1.64
Return on Assets (%)	6.47
Return on Capital (%)	9.26

Particulars	MAR 2022 (Values in Cr)
Cash & Short Term Investments	20.73
Total Assets	213.93
Total Liabilities	213.93
Total Equity	118.27
Share Outstanding	65271137
Price to Book Ratio	1.43
Return on Assets (%)	5.22
Return on Capital (%)	7.85

Particulars	MAR 2021 (Values in Cr)
Cash & Short Term Investments	23.33
Total Assets	198.77
Total Liabilities	198.77
Total Equity	106.61
Share Outstanding	65271137
Price to Book Ratio	0.61
Return on Assets (%)	0.71
Return on Capital (%)	1.07

Particulars	MAR 2020 (Values in Cr)
Cash & Short Term Investments	8.60
Total Assets	187.79
Total Liabilities	187.79
Total Equity	100.25
Share Outstanding	56839434
Price to Book Ratio	0.25
Return on Assets (%)	-7.08
Return on Capital (%)	-10.55

Particulars	MAR 2024 (Values in Cr)
Net Income	16.78
Cash from Operations	-6.07
Cash from Investing	-8.98
Cash from Financing	17.62
Net change in Cash	-1.28
Free Cash Flow	4.01

Particulars	MAR 2023 (Values in Cr)
Net Income	19.44
Cash from Operations	28.95
Cash from Investing	-26.50
Cash from Financing	4.96
Net change in Cash	5.32
Free Cash Flow	61.13

Particulars	MAR 2022 (Values in Cr)
Net Income	11.31
Cash from Operations	22.17
Cash from Investing	-16.88
Cash from Financing	-7.69
Net change in Cash	-2.57
Free Cash Flow	39.70

Particulars	MAR 2021 (Values in Cr)
Net Income	1.44
Cash from Operations	24.58
Cash from Investing	-8.36
Cash from Financing	-1.49
Net change in Cash	14.72
Free Cash Flow	26.37

Particulars	MAR 2020 (Values in Cr)
Net Income	0.03
Cash from Operations	5.64
Cash from Investing	-0.32
Cash from Financing	-5.96
Net change in Cash	-0.64
Free Cash Flow	6.31

Particulars	MAR 2024 (Values in Cr)
Net Income	17.99
Cash from Operations	-6.60
Cash from Investing	-8.99
Cash from Financing	17.63
Net change in Cash	-1.80
Free Cash Flow	3.48

Particulars	MAR 2023 (Values in Cr)
Net Income	20.65
Cash from Operations	28.80
Cash from Investing	-26.50
Cash from Financing	4.97
Net change in Cash	5.18
Free Cash Flow	60.99

Particulars	MAR 2022 (Values in Cr)
Net Income	11.31
Cash from Operations	22.38
Cash from Investing	-17.11
Cash from Financing	-7.69
Net change in Cash	-2.60
Free Cash Flow	39.90

Particulars	MAR 2021 (Values in Cr)
Net Income	1.44
Cash from Operations	24.58
Cash from Investing	-8.36
Cash from Financing	-1.49
Net change in Cash	14.72
Free Cash Flow	26.37

Particulars	MAR 2020 (Values in Cr)
Net Income	0.03
Cash from Operations	5.64
Cash from Investing	-0.32
Cash from Financing	-5.96
Net change in Cash	-0.64
Free Cash Flow	6.31

Company Name	Price	P/E	P/B	Market Cap	52 Week Low/High
BATLIBOI LTD.	99.14	39.82	1.62	340.15	75.00 / 199.80
GRAPHITE INDIA LTD	452.10	20.63	1.51	8832.93	366.00 / 709.45
CARBORUNDUM UNIVERSAL LTD	958.45	40.37	5.47	18250.61	810.00 / 1835.65
ELECON ENG. CO. LTD	436.70	26.32	5.58	9799.54	348.05 / 738.85

Company Name	Price	P/E	P/B	Market Cap	52 Week Low/High
BATLIBOI LTD.	99.14	170.93	1.85	340.15	75.00 / 199.80
GRAPHITE INDIA LTD	452.10	20.83	1.60	8832.93	366.00 / 709.45
CARBORUNDUM UNIVERSAL LTD	958.45	51.47	7.49	18250.61	810.00 / 1835.65
ELECON ENG. CO. LTD	436.70	32.54	6.77	9799.54	348.05 / 738.85

Technicals

EMA & SMA
Resistance and Support
Price Change Analysis

Bullish Moving Averages -

Bearish Moving Averages -

5 Days 38.70
26 Days 39.10
10 Days 38.30
50 Days 42.30
12 Days 38.30
100 Days 48.50
20 Days 38.60
200 Days 54.10

39.93
PIVOT

First Resistance	41.06
Second Resistance	42.73
Third Resistance	43.86

First Support	38.26
Second Support	37.13
Third Support	35.46

RSI	50.48
MACD	-0.84
Commodity Channel Index (CCI)	84.08

ADX	22.91
Williams % R	-41.26

Birla Precision Technologies L Future

Future: Price

25 May

0 100 200 300 400 500 600

Discount/Premium

25 May

0 1 2 3 4 5 6 7

Active Calls

25 May

0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul

0 500 1000 1500 2000 2500

Stock Holding

View Live Stock Screeners

Holding

Public

39.7 Promoter Holdings

60.28 FII

0.01 DII

0.0 Promoter Shares(Pledge Percentage)

0.34

Name	Category	Shares	Shares%
Birla Bombay Private Limited	Shareholding of Promoter and Promoter Group	1.6423113E7	24.89
Birla Infrastructure Limited	Shareholding of Promoter and Promoter Group	1.4015589E7	21.24
Vedant Consultancy Private Limited	Shareholding of Promoter and Promoter Group	4607663.0	6.98
Zenith Dyeintermediates	Shareholding of Promoter and Promoter Group	3939991.0	5.97
Endogram Leasing And Trading Co Pvt Ltd	Public Shareholding	1307949.0	1.98
Dheeraj Kumar Lohia	Public Shareholding	1011550.0	1.53
Mukesh	Public Shareholding	815000.0	1.24
Khopoli Investments Ltd	Shareholding of Promoter and Promoter Group	500000.0	0.76
Shearson Investment& Trading Co Pvt Ltd	Shareholding of Promoter and Promoter Group	227652.0	0.34
Yash Society	Shareholding of Promoter and Promoter Group	25056.0	0.04
Yashovardhan Birla	Shareholding of Promoter and Promoter Group	21919.0	0.03
Matri Seva Sadan Charity Trust	Shareholding of Promoter and Promoter Group	10617.0	0.02
Birla Industries Group Charity Trust	Shareholding of Promoter and Promoter Group	5947.0	0.01
Birla Shloka Edutech Limited	Shareholding of Promoter and Promoter Group	231.0	0.0
Avanti Birla	Shareholding of Promoter and Promoter Group	44.0	0.0

Birla Precision Technologies L

Ex-Date	Dividend Amt.	Dividend Type	Record Date	Instrument Type
2024-02-29	0.05	Interim	2024-02-29	Equity shares	2009-09-23	0.1	Final	2009-09-25	Equity shares	2008-09-11	1.5	Final	2008-09-15	Equity shares	2007-09-14	1.5	Final	2007-09-18	Equity shares	2005-09-08	0.0	Final	2005-09-12	Equity shares

Learn More About Stocks

Dr Reddy’s Denies Workforce Reduction Claims Amid Cost-Cut Rumours

Dr Reddy’s Laboratories rejects claims of reducing workforce costs by 25%, asserting no such plans or internal directives.

15 Apr, 2025 | 3 Min. read

Glenmark, Sun Pharma, Zydus Recall Drugs in US over Compliance Issues

Glenmark, Sun Pharma, and Zydus recall multiple drug batches in the US following manufacturing deviations and contamination concerns as per USFDA enforcement reports.

15 Apr, 2025 | 3 Min. read

HAL Denies Selecting PwC for R&D Benchmarking Amid Ongoing Bids

HAL clarifies no consultancy firm has been finalised for R&D benchmarking amid social media buzz about PwC. Selection process still ongoing via GeM portal.

15 Apr, 2025 | 3 Min. read

Aurobindo Pharma Gets USFDA Nod for Generic Xarelto 2.5mg Tablets

Aurobindo Pharma receives USFDA approval to launch generic Xarelto 2.5mg in Q1 FY26, targeting $447 million US market; higher strengths also gain tentative nod.

15 Apr, 2025 | 3 Min. read

IndiGo Becomes World’s Most Valuable Airline With $23.4 Billion Market Cap

IndiGo surpasses global peers to become the most valuable airline by market cap at $23.4 billion, pushing InterGlobe Aviation share price to record highs in 2025.

11 Apr, 2025 | 3 Min. read

SRF Ltd. Commissions New Agrochemical Unit in Dahej Worth Rs.239 Crore

SRF Ltd. starts new agrochemical facility in Dahej, Gujarat with Rs.239 crore investment. Phase 1 operational, full commissioning set for April 2025.

11 Apr, 2025 | 3 Min. read

Tata Motors’ JLR India Achieves Record Sales in FY25 at 6,183 Units

JLR India posts record-breaking FY25 retail sales of 6,183 units, up 40%. Defender leads growth, boosting Tata Motors share price sentiment.

11 Apr, 2025 | 4 Min. read

Biocon Gets USFDA Approval for Jobevne, Expands Oncology Portfolio

Biocon Biologics receives USFDA nod for cancer drug Jobevne, a bevacizumab biosimilar. Oncology portfolio in US grows, boosting Biocon Ltd. share price outlook.

11 Apr, 2025 | 3 Min. read